VIDEO: Liquid biopsies could change CRC care through early detection
Click Here to Manage Email Alerts
In this Healio video exclusive, Charles J. Meakin, MD, MHA, chief medical officer of Care Oncology, discusses risk factors for colorectal cancer, the importance of early detection and the use of liquid biopsies as screening tools.
Meakin, a board-certified radiation oncologist, said many patients avoid colonoscopies because it is an invasive procedure that requires significant preparation and time away from work.
“The good news is that we see an increase in compliance rates when people are given screening options,” Meakin said. “With a simple blood draw you can potentially find cancers before standard methods.”
According to Meakin, two blood tests, Aristotle and ColonSentry (StageZero Life Sciences), use mRNA technology to detect molecular signatures of multiple cancers from a single sample of blood. Both can aid in the early detection of CRC, which, if found in a polyp stage, almost guarantees full survival.
“Liquid biopsies have the potential to change the road map to cancer care in the United States by enabling a very easy option for earlier cancer diagnosis,” Meakin said.
Collapse
Healio Interview
Click Here to Manage Email Alerts